Treatment related acute myeloid leukemia (t-AML) is well documented phenomenon after chemotherapy. In this subgroup of patients acute promyelocytic leukemia (APML) due to delayed complication of using anthracycline is very rare occurrence. Very few cases are reported in world literature. We are reporting a rare case of occurrence of t-APML in cured breast cancer patient treated with doxorubicin. 43 year old female presented with triple negative early breast cancer treated initially with Right modified radical mastectomy. Pathological staging was pT2N0M0. She was treated with 6 cycle of adjuvant AC (Doxorubicin, Cyclophosphamide). After latent period of 23 months she developed symptoms of fever, weakness and generalized body ache. On further investigation she was found to have acute promyelocytic leukemia (APML). We had successfully treated t-APML with conventional 7+3 induction and subsequent consolidation with ATRA (All Trans Retinoic Acid) and arsenic trioxide. Patient was given maintenance treatment for 18 months after confirming negative PML RARA by RT PCR and declared cured. Patient is under regular surveillance in our centre.
INTRODUCTION
Anthracyclines are one the most common anticancer drugs used for haematological and solid malignancies. Therapy related APML (t-APML) after using anthracycline as adjuvant treatment in breast cancer is a rare entity. Very few cases are reported in the world literature till date. Treatment of t-AMPL and achieving cure is challenging. Even though anthracyclines are the causative agents for t-APML and using these drugs in the management of t-APML is an interesting feature.
CASE REPORT
43 year old pre menopausal female presented with right sided breast lump since 10 days before presenting in the clinic. Her past medical and family history was not significant. On examination there was a firm to hard lump in the right upper and outer quadrant of the breast of size 4 X 3 cm. The lump was freely movable and was not associated with any fixity to the skin or chest wall. Clinically, there was no axillary lymphadenopathy. Her preoperative baseline biochemical and radiological investigations were within the normal range. She was treated with right MRM (modified radical mastectomy) and pathological staging was pT2N0M0. Patient's cardiac function evaluated by 2D ECHO, which was normal. Patient was given 6 cycles of adjuvant AC. Dose of Doxorubicin was 60 mg/m2 and Cyclophosphamide was 600 mg/ m2 per cycle at the interval of 21 days. Total cumulative dose of Doxorubicin was 360 mg/m2. She was put on maintenance treatment inform of 6-mercaptopurine 50 mg daily and weekly oral methotrexate 15 mg/m 2 . ATRA was given at a dose of 45 mg/m 2 every 3 monthly for 15 days. Total duration of maintenance was 18 months. She was declared cured after again confirming molecular remission by RT PCR. Patient is under regular surveillance in our tertiary care centre with yearly mammosonography and monthly CBC and platelets since one and half year.
DISCUSSION
Anthracyclines are one of the most common chemotherapy medications used worldwide. It is especially true for India as large number of breast cancer patients diagnosed early due to improved literacy rate and nationwide screening programs. True incidence of t-APML after using anthracycline is unknown due to rarity of its occurrence. 1, 2 Doxorubicin induced t-APML results from DNA cleavage by topoisomerase 2 and resulting genetic alteration in form of chromosome translocations and subsequent t-APML. Some evidence support a direct role of topoisomerase II in causing the DNA damage that leads to chromosomal rearrangements. An indirect mechanism involving induction of apoptosis inducing nucleases has also been proposed. 3 Doxorubicin also causes an increase in the concentration of breakpoint complexes. All these mechanisms lead to cleavage of PML and RARA and formation of t (15; 17). Median latent period of t-APML is 25-29 months. In our case, latent period was 23 months. Haematological and marrow characteristic of t-APML are same as primary APML but cytogenetic characteristics are different. There are more rearrangements in chromosomes 5, 7 or 17 and less trisomy of 8 are seen in t-APML as compared to non t-APML. In our case conventional cytogenetic was normal. Outcome is similar as in non t-APML. 2 Rechallenging again with anthracycline as induction treatment of t-APML is an interesting aspect. Hu J et al. demonstrated Long-term efficacy and safety of 85 patients who diagnosed as de novo APML and received arsenic trioxide/ATRA. 6 Chemotherapy was given as induction if white blood counts were more than 10,000, Chemotherapy was given in as induction if count white blood counts were more than 10,000, routinely in consolidation and in maintenance at a low dose. Complete remission (CR) was seen in 94.1% of patients. Five-year overall survival (OS) for all patients was 92%. Study concluded that prognosis is not influenced by day1 white blood cell counts, different subtypes of PML-RARA translocation, or FLT3 mutations Dayyani. et al 4 studied 29 patients of t-APML and compared outcome of who treated with ATRA + chemotherapy and ATRA + ATO. Author concluded later regimen did not detect inferior results compare to former. We did not use daunorubicin as consolidation treatment as cumulative dose for cardio toxicity that is 450 mg/m 2 would be crossed (after calculating dose conversion with doxorubicin). Considering our limited resources, management of such case was challenging.
CONCLUSION
It is likely that parallel to increase of use of anthracycline for various malignancies, the incidence of t-APML has increased. Its presentation, management and outcome are similar to non t-APML Anthrayclines can be used during induction or consolidation therapy of APML therapy until the ceiling dose of the drugs are reached and later can be replaced with arsenic trioxide and it is clinically challenging and desirable.
